तुलना करने के लिए मीट्रिक्स | ADAG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधADAGपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −11.5x | −3.4x | −0.4x | |
PEG अनुपात | −0.30 | −0.28 | 0.00 | |
क़ीमत/बुक | 2.6x | 4.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 25.4x | 24.4x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 154.6% | 133.7% | 47.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.8% | 6.5% | अनलॉक करें |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.